1. Home
  2. BBDC vs PHVS Comparison

BBDC vs PHVS Comparison

Compare BBDC & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBDC
  • PHVS
  • Stock Information
  • Founded
  • BBDC 2006
  • PHVS 2015
  • Country
  • BBDC United States
  • PHVS Switzerland
  • Employees
  • BBDC N/A
  • PHVS N/A
  • Industry
  • BBDC Diversified Financial Services
  • PHVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BBDC Finance
  • PHVS Health Care
  • Exchange
  • BBDC Nasdaq
  • PHVS Nasdaq
  • Market Cap
  • BBDC 961.0M
  • PHVS 980.9M
  • IPO Year
  • BBDC 2007
  • PHVS 2021
  • Fundamental
  • Price
  • BBDC $9.49
  • PHVS $24.42
  • Analyst Decision
  • BBDC Buy
  • PHVS Buy
  • Analyst Count
  • BBDC 3
  • PHVS 6
  • Target Price
  • BBDC $9.67
  • PHVS $37.17
  • AVG Volume (30 Days)
  • BBDC 383.7K
  • PHVS 33.8K
  • Earning Date
  • BBDC 08-07-2025
  • PHVS 08-13-2025
  • Dividend Yield
  • BBDC 10.92%
  • PHVS N/A
  • EPS Growth
  • BBDC N/A
  • PHVS N/A
  • EPS
  • BBDC 0.94
  • PHVS N/A
  • Revenue
  • BBDC $280,800,000.00
  • PHVS N/A
  • Revenue This Year
  • BBDC N/A
  • PHVS N/A
  • Revenue Next Year
  • BBDC N/A
  • PHVS N/A
  • P/E Ratio
  • BBDC $10.17
  • PHVS N/A
  • Revenue Growth
  • BBDC N/A
  • PHVS N/A
  • 52 Week Low
  • BBDC $7.66
  • PHVS $11.51
  • 52 Week High
  • BBDC $10.85
  • PHVS $25.76
  • Technical
  • Relative Strength Index (RSI)
  • BBDC 66.32
  • PHVS 73.80
  • Support Level
  • BBDC $9.18
  • PHVS $17.63
  • Resistance Level
  • BBDC $9.37
  • PHVS $25.76
  • Average True Range (ATR)
  • BBDC 0.12
  • PHVS 1.51
  • MACD
  • BBDC 0.03
  • PHVS 0.69
  • Stochastic Oscillator
  • BBDC 99.80
  • PHVS 82.19

About BBDC Barings BDC Inc.

Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. Barings employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: